Validation of dosimetry programs (Olinda & IDAC) for evaluation of absorbed dose in 177LuPSMA therapy of metastatic castration-resistant prostate cancer (mCRPC) using Monte Carlo simulation

被引:0
|
作者
Maroufpour, Sirwan [1 ]
Aryana, Kamran [2 ]
Nasseri, Shahrokh [1 ]
Fazeli, Zahra [2 ]
Arabi, Hossein [3 ]
Momennezhad, Mehdi [1 ]
机构
[1] Mashhad Univ Med Sci, Fac Med, Med Phys Grp, Mashhad, Iran
[2] Mashhad Univ Med Sci, Imam Reza Hosp, Fac Med, Nucl Med Res Ctr, Mashhad, Iran
[3] Geneva Univ Hosp, Div Nucl Med & Mol Imaging, Geneva, Switzerland
来源
EJNMMI PHYSICS | 2024年 / 11卷 / 01期
关键词
Prostate cancer; Lu-177-PSMA; IDAC; OLINDA; GATE; Dosimetry; RADIOLIGAND THERAPY; RADIONUCLIDE THERAPY; NORMAL ORGANS; SPECT; INHIBITOR; RISK;
D O I
10.1186/s40658-024-00691-7
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: Clinical trials have yielded promising results for (177)Lutetium Prostate Specific Membrane Antigen (Lu-177-PSMA) therapy in metastatic castration resistant prostate cancer (mCRPC) patients. However, the development of precise methods for internal dosimetry and accurate dose estimation has been considered ongoing research. This study aimed to calculate the absorbed dose to the critical organs and metastasis regions using GATE 9.0 Monte Carlo simulation (MCS) as a gold standard to compare the OLINDA 1.1 and IDAC 2.1 software. Material and Methods: This study investigated absorbed doses to different organs in 9 mCRPC patients during their first treatment cycle. Whole-body planar images were acquired at 1 +/- 0.5, 4 +/- 0.5, 24 +/- 2, 48 +/- 2, 72 +/- 2, and 144 +/- 2 h post-injection, with SPECT/CT images obtained at 24 +/- 2 h. Absorbed doses were calculated for five organs and the entire metastasis regions using GATE, OLINDA, and IDAC platforms. The spherical method was used to determine and compare the absorbed doses in metastatic regions and undefined organs in OLINDA and IDAC Phantom. Results: The organ-absorbed dose calculations produced by GATE were consistent with those obtained from OLINDA and IDAC. The average percentage differences in absorbed dose for all organs between Monte Carlo calculations and the estimated from IDAC and OLINDA were -0.24 +/- 2.14% and 5.16 +/- 5.66%, respectively. There was a significant difference between GATE and both IDAC (17.55 +/- 29.1%) and OLINDA (25.86 +/- 18.04%) in determining absorbed doses to metastatic areas using the spherical model. Conclusion: The absorbed dose of organs in the first treatment cycle remained below tolerable limits. However, cumulative absorbed doses should be considered for the administered activities in the next cycles of treatment. While Monte Carlo, IDAC, and OLINDA results were aligned for organ dose calculations, patient-specific dosimetry may be necessary due to anatomical and functional changes. Accurate dose estimation for undefined organs and metastatic regions using the spherical model is significantly influenced by tissue density, highlighting the value of CT imaging.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Radiobiological parameters for the assessment of 177LuPSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
    Hu, J.
    Xue, S.
    Mercolli, L.
    Hasan, S.
    Rominger, A.
    Afshar-Oromieh, A.
    Shi, K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1193 - S1193
  • [2] Radiation Dosimetry for 177Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions
    Okamoto, Shozo
    Thieme, Anne
    Allmann, Jakob
    D'Alessandria, Calogero
    Maurer, Tobias
    Retz, Margitta
    Tauber, Robert
    Heck, Matthias M.
    Wester, Hans-Juergen
    Tamaki, Nagara
    Fendler, Wolfgang P.
    Herrmann, Ken
    Pfob, Christian H.
    Scheidhauer, Klemens
    Schwaiger, Markus
    Ziegler, Sibylle
    Eiber, Matthias
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (03) : 445 - 450
  • [3] First-Strike Rapid Predictive Dosimetry and Dose Response for 177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
    Kao, Yung Hsiang
    Falzone, Nadia
    Pearson, Michael
    Sivaratnam, Dinesh
    JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY, 2024, 52 (03)
  • [4] Cost Utility Analysis of 177Lu-PSMA-617 Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC) in Germany
    Stargardt, T.
    Brinkmann, C.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S827 - S827
  • [5] 177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer
    Fendler, Wolfgang P.
    Kratochwil, Clemens
    Ahmadzadehfar, Hojjat
    Rahbar, Kambiz
    Baum, Richard P.
    Schmidt, Matthias
    Pfestroff, Andreas
    Luetzen, Ulf
    Prasad, Vikas
    Heinzel, Alexander
    Heuschkel, Martin
    Ruf, Juri
    Bartenstein, Peter
    Krause, Bernd J.
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2016, 55 (03): : 123 - 128
  • [6] Final results of 2-dose fractionation of 177mLu-J591 for progressive metastatic castration-resistant prostate cancer mCRPC).
    Tagawa, Scott T.
    Batra, Jaspreet
    Vallabhajosula, Shankar
    Jhanwar, Yuliya
    Christos, Paul J.
    Emmerich, Lauren
    Karir, Beerinder S.
    Karpenko, Irene
    Lam, Linda
    Febles, Victor R. A.
    Molina, Ana M.
    Beltran, Himisha
    Goldsmith, Stanley J.
    Bander, Neil Harrison
    Nanus, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Dual antiangiogenic therapy using lenalidomide and bevacizumab with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Adesunloye, Bamidele
    Huang, Xuan
    Ning, Yangmin M.
    Madan, Ravi A.
    Gulley, James L.
    Beatson, Melony
    Kluetz, Paul Gustav
    Adelberg, David E.
    Arlen, Philip M.
    Parnes, Howard L.
    Mulquin, Marcia
    Steinberg, Seth M.
    Wright, John Joseph
    Trepel, Jane B.
    Dawson, Nancy Ann
    Chen, Clara
    Bassim, Carol
    Apolo, Andrea Borghese
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Efficacy of systemic therapy following [177Lu] Lu-PSMA in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Kostos, Louise Kathleen
    Lai, William Yu Ching
    Lambroglou, Peter
    Medhurst, Elizabeth
    Buteau, James Patrick
    Sandhu, Shahneen
    Tran, Ben
    Spain, Lavinia Anne
    Conduit, Ciara
    Wallace, Roslyn
    Alipour, Ramin
    Akhurst, Timothy J.
    Kong, Grace
    Cardin, Anthony
    Saghebi, Javad
    Kumar, Aravind Ravi
    Hofman, Michael S.
    Azad, Arun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [9] Final results of phase I/II trial of fractionated dose 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC)
    Tagawa, S. T.
    Sun, M.
    Sartor, O.
    Thomas, C.
    Molina, A. M.
    Sternberg, C. N.
    Nanus, D. M.
    Osborne, J.
    Bander, N.
    ANNALS OF ONCOLOGY, 2021, 32 : S645 - S645
  • [10] Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy
    Fadi Khreish
    Niklas Kochems
    Florian Rosar
    Amir Sabet
    Martin Ries
    Stephan Maus
    Matthias Saar
    Mark Bartholomä
    Samer Ezziddin
    European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 103 - 112